Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health"
16.5.2019 09:00:00 EEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515006091/en/
Takeda’s donation will enable LSHTM to recruit a world-class researcher and educator to join its innovative academic team as the first holder of the Takeda Chair in Global Child Health. This post will play a critical role in consolidating LSHTM’s child health research across more than 100 countries, accelerating change for one of the biggest global health challenges, and further strengthening LSHTM’s position as a leader in maternal, child and adolescent health.
Christophe Weber, President and CEO of Takeda, stated, “Takeda’s aim is to thrive at the cutting edge of innovation that helps solve unmet medical needs, both through our own R&D and in collaboration with exceptional partners across the globe. We believe that global health research and the training of new global healthcare professionals are essential to the ongoing translation of science into life-changing therapies for patients. This Chair does both. We are excited to partner with LSHTM, renowned for its pioneering research and uniquely placed to realize the full potential impact of the Chair, and in doing so directly benefitting millions of children and their families.”
Through its Corporate Social Responsibility (CSR) activities, Takeda has supported health worker training and capacity building, immunization campaigns, health system strengthening and maternal, child and newborn health in the developing world for over a decade. Additionally, Takeda has a long history of supporting child health beyond CSR. For over 70 years, the company has supplied critical vaccines to the children of Japan, and more recently is working to expand impact on global health beyond Japan through a pipeline with the potential to transform the global picture for several neglected diseases.
More than five million children under the age of five die each year, half of whom die within the neonatal period (birth to one month old), with the next largest number being due to childhood infections such as pneumonia and diarrhea. While the vast majority of these deaths are preventable, key research gaps remain. The Takeda Chair in Global Child Health will enable a ‘rising star’ to bridge research, public policy, and healthcare delivery by developing thought leadership in child survival and health through innovative research, including vaccines, neonatal care, under-nutrition, and infection diagnostics and treatments.
Professor Baron Peter Piot, Director of LSHTM, stated, “We are honored to partner with Takeda to create this Professorial Chair, the first in our School’s history to have been fully endowed through corporate support. This donation is incredibly valuable, providing ongoing funding and support for a Professorial Chair in Global Child Health – a pivotal part of our continuing mission to improve health worldwide. We are deeply thankful to Takeda for their generosity as we work together to transform the health of future generations.”
Professor Joy Lawn, Director of LSHTM’s MARCH Centre (Maternal Adolescent, Reproductive & Child Health Centre), said, “The Takeda Chair will advance the evidence base for child survival and child health around the world, enable innovations and drive an important emphasis on the science and realities of healthcare implementation. This Chair will be instrumental in linking evidence to action, especially in sub-Saharan Africa and South Asia, where the majority of child deaths occur. We are grateful for Takeda’s generous support which will advance child health worldwide, and aligns with the mission of the London School of Hygiene & Tropical Medicine and our school’s MARCH Centre.”
International recruitment for the Takeda Chair in Global Child Health will begin in May. Due to the perpetual nature of this endowment, this role will be awarded to generations of academics, enabling the best and brightest academic minds to have the freedom to explore innovative ways to improve global health.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
About the London School of Hygiene & Tropical Medicine
The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with 4,500 students and more than 3,000 staff working in over 100 countries. LSHTM is one of the highest-rated research institutions in the UK, and among the world's leading schools in public and global health. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. For more information, visit www.lshtm.ac.uk and https://march.lshtm.ac.uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515006091/en/
Contact information
Media Inquiries:
The Press Office at LSHTM
press@lshtm.ac.uk
+44(0)207
927 2802
Takeda Pharmaceutical Company
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81
3 3278 2095
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release
Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i
NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 16:08:00 EET | Press release
NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115196647/en/ NIKE, Inc. is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. Elite marathoners. Backyard hoopers. An athlete* walking into the gym for the first time. Every athlete NIKE, Inc. works alongside pushes the company to imagine what doesn’t yet exist, then make those possibilities real. Today, NIKE, Inc. is showing what comes next. As part of its World of Athletes* showcase in Beaverton, Ore., the company is unveiling Tuned Air, the next frontier of Nike Air; new Nike Mind and Nike Free footwear, platforms built to scale across sport; innovation
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release
Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 14:00:00 EET | Press release
The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “For generations, Bacardi has had a front-row seat to what’s next in drinks. By combining insights from bar teams, leading venues
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release
Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
